Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity (mobocertinib) in China. The Japanese pharmaceutical giant will partner with China-based health platform MediTrust Health to launch innovative payment solutions for the drug in China, making this advanced therapy more accessible to patients.
Clinical Need and Exkivity’s Role
Patients with advanced non-small cell lung cancer (NSCLC) carrying the EGFR 20 exon insertion mutation face a poorer survival prognosis compared to those with common EGFR mutations. Real-world studies have shown that without targeted and effective treatment, the objective response rate (ORR) of patients with advanced EGFR 20 exon insertion mutation after second-line and post-line treatment is less than 10%, with a progression-free survival (PFS) of only 3.7 months and an overall survival (OS) of just 13.6 months.
Exkivity’s Clinical Success
Mobocertinib, the world’s first and currently only orally targeted therapy specifically designed to treat EGFR exon20ins advanced NSCLC, was approved for use in adult patients with locally advanced or metastatic NSCLC who have progressed during or after platinum-containing chemotherapy and carry mutations in exon 20 epidermal growth factor receptor (EGFR). A clinical study demonstrated that after 25.8 months of long-term follow-up, the drug increased the median progression-free survival (mPFS) of patients to 7.3 months, and the median overall survival (mOS) reached 20.2 months, significantly improving patient outcomes.-Fineline Info & Tech
